KR20220017989A - Prmt5 억제제를 사용하여 암을 치료하는 방법 - Google Patents

Prmt5 억제제를 사용하여 암을 치료하는 방법 Download PDF

Info

Publication number
KR20220017989A
KR20220017989A KR1020227000036A KR20227000036A KR20220017989A KR 20220017989 A KR20220017989 A KR 20220017989A KR 1020227000036 A KR1020227000036 A KR 1020227000036A KR 20227000036 A KR20227000036 A KR 20227000036A KR 20220017989 A KR20220017989 A KR 20220017989A
Authority
KR
South Korea
Prior art keywords
cancer
days
period
subsequent
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227000036A
Other languages
English (en)
Korean (ko)
Inventor
힐러리 조이 밀러 퀸
캐서린 엘리자베스 팩맨
나홀 하디쉬-버헤인
기어트 에스.제이. 매넨스
준궈 저우
안토니 티. 그리웨이
더크 브레머
예 구오
통페이 우
홍 씨에
조쉬 라우링
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20220017989A publication Critical patent/KR20220017989A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227000036A 2019-06-06 2020-06-05 Prmt5 억제제를 사용하여 암을 치료하는 방법 Ceased KR20220017989A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858076P 2019-06-06 2019-06-06
US62/858,076 2019-06-06
EP19193850.5 2019-08-27
EP19193850 2019-08-27
PCT/EP2020/065639 WO2020245365A1 (en) 2019-06-06 2020-06-05 Methods of treating cancer using prmt5 inhibitors

Publications (1)

Publication Number Publication Date
KR20220017989A true KR20220017989A (ko) 2022-02-14

Family

ID=70922068

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227000036A Ceased KR20220017989A (ko) 2019-06-06 2020-06-05 Prmt5 억제제를 사용하여 암을 치료하는 방법

Country Status (16)

Country Link
US (2) US11571437B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980019A1 (cg-RX-API-DMAC7.html)
JP (1) JP7590351B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017989A (cg-RX-API-DMAC7.html)
CN (1) CN113966232A (cg-RX-API-DMAC7.html)
AU (1) AU2020286961A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024469A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142825A1 (cg-RX-API-DMAC7.html)
IL (1) IL288665A (cg-RX-API-DMAC7.html)
JO (1) JOP20210320A1 (cg-RX-API-DMAC7.html)
MA (1) MA56095A (cg-RX-API-DMAC7.html)
MX (1) MX2021014944A (cg-RX-API-DMAC7.html)
PH (1) PH12021552841A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112439YA (cg-RX-API-DMAC7.html)
TW (1) TW202112375A (cg-RX-API-DMAC7.html)
WO (1) WO2020245365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153161A1 (en) * 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115161341B (zh) * 2022-06-10 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
WO2003070739A1 (en) 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
EP1645561A1 (en) 2003-07-15 2006-04-12 Mitsui Chemicals, Inc. Method of synthesizing cyclic bisdinucleoside
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2011075665A2 (en) 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012083170A1 (en) 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
EP2694524B1 (en) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
JP6510485B2 (ja) * 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Prmt5インヒビターおよびそれらの使用方法
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
BR112019006414A2 (pt) 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
SG11201907607VA (en) 2017-02-27 2019-09-27 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MX2020005944A (es) 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.

Also Published As

Publication number Publication date
JP2022535406A (ja) 2022-08-08
TW202112375A (zh) 2021-04-01
CA3142825A1 (en) 2020-12-10
JP7590351B2 (ja) 2024-11-26
WO2020245365A1 (en) 2020-12-10
CN113966232A (zh) 2022-01-21
BR112021024469A2 (pt) 2022-01-18
JOP20210320A1 (ar) 2023-01-30
SG11202112439YA (en) 2021-12-30
US20230241087A1 (en) 2023-08-03
MX2021014944A (es) 2022-01-24
AU2020286961A1 (en) 2022-02-03
US20200384006A1 (en) 2020-12-10
IL288665A (en) 2022-02-01
EP3980019A1 (en) 2022-04-13
PH12021552841A1 (en) 2022-10-03
US11571437B2 (en) 2023-02-07
MA56095A (fr) 2022-04-13

Similar Documents

Publication Publication Date Title
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
JP2024516972A (ja) Raf阻害薬による癌の処置
EA034512B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
US20230241087A1 (en) Methods Of Treating Cancer Using Prmt5 Inhibitors
TW201628621A (zh) 泛素活化酶抑制劑及輻射之施用
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
WO2023056431A1 (en) Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
JP2023509191A (ja) 癌を治療するための組み合わせ療法
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
CN113747898A (zh) 用于联合治疗软组织肉瘤的喹啉衍生物
HK40067831A (en) Methods of treating cancer using prmt5 inhibitors
JP2019532937A (ja) Rnaポリメラーゼi阻害に基づく、がんの併用治療戦略
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
US12612395B2 (en) Rocaglate derivatives and uses thereof
RU2832833C1 (ru) Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком
AU2024351866A1 (en) Novel combination therapy for blood cancer
JP2025533522A (ja) 脳腫瘍、乳癌、膵臓癌、及び肺癌の治療に使用されるバノキセリン
HK40112852A (en) Pharmaceutical for treating or preventing cancer
JP2023519491A (ja) 癌関連疲労の治療に使用するためのcxcl8阻害剤およびその医薬組成物
JP2024509472A (ja) Fgfr2及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
EA052060B1 (ru) Виды лечения рака с применением ингибиторов prmt5, действующих совместно с mta
JP2004359545A (ja) 抗癌剤耐性克服剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601